SCHEMBL257368

SCHEMBL257368

Cc1ccc(C(=O)c2ccc(F)cc2)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.56
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
HTT P42858 1/20 0.49
SRD5A2 P31213 1/20 0.49
LTA4H P09960 1/20 0.47
HPGD P15428 2/20 0.46
MAPT P10636 3/20 0.46
MEN1 O00255 1/20 0.46
HTR1E P28566 1/20 0.46
KMT2A Q03164 1/20 0.46
S1PR3 Q99500 1/20 0.46
CHRNA1 P02708 1/20 0.45
CHRNG P07510 1/20 0.45
CHRNB1 P11230 1/20 0.45
CHRNB2 P17787 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924706 0.89 HPGD (0.54) SMN1; SMN2NPC1RAB9ACYP3A4HTT
SCHEMBL257653 0.85 ALDH1A1 (0.61) SMN1; SMN2RAB9AHTTSRD5A2HPGD
SCHEMBL15100942 0.85 SRD5A2 (0.53) SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT
SCHEMBL15100600 0.85 CES2 (0.50) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL15100603 0.85 NPC1 (0.48) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL13176761 0.84 ATM (0.55) SMN1; SMN2NPC1RAB9AHTTSRD5A2
SCHEMBL8612482 0.83 SRD5A2 (0.69) SMN1; SMN2NPC1RAB9ASRD5A2LTA4H
SCHEMBL15197082 0.83 SMN1; SMN2 (0.69) SMN1; SMN2NPC1RAB9AHTTLTA4H
SCHEMBL10046987 0.82 CES2 (0.47) SMN1; SMN2NPC1RAB9ACYP1A2CYP3A4
SCHEMBL1651161 0.81 SRD5A2 (0.52) SMN1; SMN2NPC1RAB9ASRD5A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 EP disclosed
WO-2012029942-A1 CYCLIC AMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 SMN1; SMN2 2704/4885NPC1 1990/4885RAB9A 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.